For Healthcare Professionals Only
Commercial Benefits & Common Questions
Zollara Vision Services enables UK opticians and optometrists to offer Valeda® photobiomodulation treatment without the financial burden of device ownership. This model is designed to reduce capital risk whilst allowing practices to introduce an evidence-based clinical service for patients with dry age-related macular degeneration.
Understanding the Zollara Vision Services Model
Zollara Vision Services provides a turnkey solution for practices wishing to offer Valeda® treatment to suitable patients. Rather than purchasing equipment outright, practices work in partnership with Zollara Vision Services to deliver the service within their own clinical environment.
This arrangement is structured to align commercial opportunity with clinical autonomy. Practices maintain full control over patient selection, treatment protocols, and pricing decisions, whilst Zollara Vision Services manages device provision, technical support, and regulatory compliance.
The model has been developed specifically for the UK optical sector, recognising the operational realities faced by independent and small group practices.
Key Points
- No device purchase required
- Clinical autonomy preserved
- Designed for UK practices
- Regulatory compliance managed
Key Commercial Benefits
No Capital Expenditure
Eliminate the upfront investment typically associated with introducing new clinical technology. Practices avoid equipment purchase costs, maintenance contracts, and depreciation concerns.
Pricing Autonomy
Retain complete control over patient pricing decisions. Set fees that reflect your local market, overheads, and clinical positioning without external restriction.
Revenue Opportunity
Create a new income stream aligned with your existing clinical services. Offer patients an evidence-based treatment option whilst generating practice revenue.
Reduced Operational Burden
Zollara Vision Services manages device provision, servicing, calibration, and regulatory obligations, allowing you to focus on clinical delivery and patient care.
This model is particularly suited to practices seeking to expand their dry AMD service offering without committing significant capital or taking on long-term equipment liabilities. All clinical decisions remain entirely within the professional judgement of the treating optometrist or ophthalmologist.
Illustrative Example Only
Financial Illustration
The figures below are provided as an illustrative example only to demonstrate how the commercial arrangement may operate. Actual figures will vary according to practice pricing decisions, patient demographics, and treatment volumes.
1
Patient Fee
£1,400 per treatment cycle
(Illustrative only. Practice sets own pricing.)
2
Service Fee to Zollara
£700 per treatment cycle
(Illustrative only. Invoiced per treatment.)
3
Practice Revenue
£700 per treatment cycle
(Illustrative only. No revenue guarantee implied.)
Important Commercial Disclaimers
- All figures shown are indicative only and do not constitute a revenue forecast or guarantee
- Practices determine their own patient pricing based on local market conditions and business requirements
- No guarantee is made regarding patient uptake, treatment volumes, or financial outcomes
- Actual commercial performance will depend on multiple factors including patient demographics, clinical suitability, and practice location
Billing & Financial Flow
The financial arrangement is structured to maintain clear separation between practice-patient transactions and the commercial relationship between the practice and Zollara Vision Services.
Practice Invoices Patient
The practice issues an invoice directly to the patient for Valeda® treatment at the fee determined by the practice.
Zollara Invoices Practice
Zollara Vision Services invoices the practice on a per-treatment-cycle basis following treatment delivery.
No Patient Billing from Zollara
Zollara Vision Services does not bill patients directly. The patient relationship remains with the practice.
This structure ensures that practices maintain direct control of patient transactions and billing relationships. Payment terms between Zollara Vision Services and the practice are agreed during onboarding and documented in the service agreement.
Common Questions – Clinical & Operational
Do we need to buy the Valeda® device?
No. Zollara Vision Services provides access to the device under a service arrangement. There is no requirement to purchase equipment or enter into leasing agreements.
Who holds clinical responsibility?
Clinical responsibility remains entirely with the treating eye care professional. Zollara Vision Services does not diagnose, prescribe, or determine patient suitability. All treatment decisions are made by the clinician.
Where is treatment delivered?
Treatment is delivered within your own practice premises. Zollara Vision Services arranges device installation, training, and ongoing technical support at your location.
Regulatory Note: All clinical decisions remain the responsibility of the treating eye care professional. Zollara Vision Services does not diagnose, prescribe, or bill patients. Information on this page is for healthcare professionals only.
Common Questions – Commercial & Next Steps
Is the arrangement exclusive?
Practices are not required to commit to exclusivity. You remain free to offer other treatments and work with other providers as your clinical judgement dictates.
How long does onboarding take?
Typical onboarding, including installation, staff training, and operational setup, takes approximately 4–6 weeks from agreement signature, subject to practice availability and site requirements.
What happens if we choose not to proceed?
The Letter of Intent (LOI) is entirely non-binding. If you decide the service is not suitable for your practice, there is no obligation to proceed beyond initial discussions.
Next Steps
If you would like to explore whether Zollara Vision Services might suit your practice, we invite you to request further information or arrange an introductory call. The Letter of Intent is non-binding and designed simply to establish mutual professional interest.
Valeda® is a trademark of LumiThera, Inc. | Information for healthcare professionals only. | Zollara Vision Services is a division of Zollara Ltd.